

Press Release

Eurofins Medinet Expands Capabilities to Provide Global Infectious Disease Services

October 19, 2009 - Washington, DC

As infectious diseases continue to be a leading cause of morbidity and mortality throughout the world, Eurofins Medinet has made a commitment to be the global leader in laboratory and consultative services that support the development of products for preventing, controlling, and treating infectious diseases throughout the world.

In support of this commitment Eurofins Medinet, Washington, DC (WDC) relocated to a new 33,000 square foot state-of-the-art facility in September of 2008 that is well designed to streamline sample processing, increase our capacity for global clinical trials, and complement our other state-of-the-art facilities in both Europe (Breda and Paris) and Asia (Shanghai and Singapore). Globally, Eurofins Medinet is able to provide several key laboratory services critical to the development of products for the prevention and treatment of infectious diseases. These areas include toxicology, pharmacology, bioanalytics, biomarker development, and genomics. Most recently Eurofins Medinet has expanded its diagnostic virology program to support pre-clinical development of anti-viral products and global clinical trials for anti-viral agents, vaccines, and immuno-modulating products.

With this broad scope of laboratory capabilities offered globally, Eurofins Medinet is strongly and uniquely positioned to support all stages of anti-infective product development, from discovery through regulatory approval, and beyond.

For more information about Eurofins Medinet, please visit us online at www.eurofinsmedinet.com or contact:

Eurofins Medinet Washington DC
Tel: +1 703 480-2500
Fax: +1 703 480-2654
Email: info@eurofinsmedinet.com

Eurofins Medinet Breda
Tel: +31 (0) 76 572 72 72
Fax: +31 (0) 76 573 77 78
Email: info@eurofinsmedinet.com

Notes for the editor:

About Eurofins Medinet

Eurofins Medinet provides a full range of global central laboratory testing services including safety parameters, biomarker development and analysis, and specialized testing in bioanalysis, pharmacokinetics, microbiology and genomics using its fully standardized and accredited central laboratories in Breda, the Netherlands, Washington DC and Denver USA, Paris, France, Singapore and Shanghai, China.

Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With about 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.